Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)

Key facts

Sponsor

The Second Affiliated Hospital of Fujian Medical University

Principal Investigator

Hongzhi Gao, Dr.

The Second Affiliated Hospital of Fujian Medical University

Intervention

NK cells(biological)

Enrollment

15 target

Eligibility

18-75 years · All sexes

Timeline

2016 – 2017

Study locations (1)

• The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Collaborators

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tropical spastic paraparesis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT04799288
  Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
  National Institute of Neurological Disorders and Stroke (NINDS)
• RECRUITINGNCT00001778
  Evaluation of Patients With HAM/TSP
  National Institute of Neurological Disorders and Stroke (NINDS)

See all trials for Tropical spastic paraparesis →